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Abstract The impact of this pandemic is not only through COVID-19 itself: the 
care for non-COVID-19 related conditions has been dramatically curtailed, shaking 
entire healthcare services around the world. Amongst the non-COVID-19 related 
conditions, oncology has been disproportionally affected. We discuss how oncology 
has changed since the acute phase of the pandemic; its impact on clinicians, trainees, 
and patients; and offer some medical and historical perspectives to reflect on how 
this impact could be reduced.
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1  Impact of COVID‑19 on oncology
In this short commentary we wish to explore the question of the impact of COVID-
19 on oncology. Our interest in this question stems from our experience and exper-
tise in public health, and healthcare workforce training and burnout. Moreover, 
being one of us a practicing oncologist in Europe, oncology was chosen as a case 
study for its relevant impact on health care systems, and more in general on patients’ 
health. This commentary has many limitations—for example it will not represent 
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the patient perspective, but it will mostly focus on our areas of expertise outlined 
above. Our aim is to encourage more serious thinking around an area that is becom-
ing increasingly pressing and that deserves much more discussion.
A survey of 155 countries conducted by the World Health Organization (WHO) 
in May 2020 reported that the COVID-19 pandemic has curtailed the provision of 
health services for non-communicable diseases (Dyer 2020). Key resources, ser-
vices, and healthcare staff have been re-directed towards COVID-19. Oncology care, 
which often involves extensive surgery, immune suppressive therapy and inpatient 
treatment, has been disproportionally affected (Rosenbaum 2020). Oncologists in 
many countries have been redeployed to help colleagues dealing with COVID-19 
patients, and ‘non-essential’ tests and screenings have been cancelled or postponed 
(The Lancet Oncology 2020). These changes resulted in the closure of screening and 
diagnostic services, a slowing down or complete cessation of referrals, significant 
delays and difficulties in accessing chemotherapy, and, at least in some instances, 
the delivery of suboptimal care. Such changes were justified as a way to minimise 
risks of oncology patients—many of whom are considered vulnerable—contract-
ing COVID-19 and worsening their condition (The Lancet Oncology 2020). How-
ever, these changes resulted also in a worrying decrease in cancer diagnoses, and an 
increase in cancer deaths (Jones et al. 2020).
Moreover, the impact of COVID-19 on oncology has hit the wider oncology 
community, from research and collaborations, to education and clinical training 
(The Lancet Oncology 2020). For example, COVID-19 has drastically impacted the 
way oncology is taught in Universities and at postgraduate level. In-person classes 
were put on hold during the acute phase of COVID-19 pandemic, to comply with 
social distancing measures, and protect students’ health. Hands-on teaching has 
been replaced by webinars and online resources. Video conference-based case dis-
cussions have been used as proxy of real case management (The Lancet Oncology 
2020). Will these changes have an impact on the skills and competences of future 
oncologists? Academic bodies, together with student representatives, are consider-
ing a blended model of medical teaching. The use of online platforms might replace 
frontal lessons, but clinical experience cannot be substituted and should be gradu-
ally re-introduced, maintaining the flexibility and adaptiveness needed in this new 
situation.
2  A slow return to ‘normality’?
Dealing with the urgent and growing oncology patient backlog after the peak of the 
pandemic is proving incredibly challenging.
In England alone, experts have estimated that as a direct result of not having 
received healthcare in recent months 30,000 to 40,000 patients could not start oncol-
ogy treatment, and between 7000 and 35,000 of those could die in the next year.1
1 https ://www.thegu ardia n.com/world /2020/aug/06/nhs-shutd own-risks -thous ands-of-death s-in-covid 
-19-secon d-wave (last accessed 07/09/2020).
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Some oncology patients may also still feel unsafe in hospital or primary care 
settings, and/or may not want to burden healthcare professionals (in the UK there 
have been 60% fewer referrals than usual since the pandemic (Jones et al. 2020)). 
Although the uptake of telemedicine may help reaching some patients with potential 
cancer symptoms needing urgent assessment—this and other forms of remote medi-
cine may not be accessible to patients from low socioeconomic backgrounds, thus 
exacerbating inequalities in cancer diagnosis and care (Jones et  al. 2020). Moreo-
ver, clinicians themselves need to acquire new skills e.g. how to use telemedicine 
platforms appropriately, or assessing patients who are wearing face coverings. Some 
oncology healthcare professionals have experienced significant burnout, as a conse-
quence of having worked in COVID-19 hospitals, moral injury resulting from being 
unable to give patients the best care due limited resources, and a lack of organisa-
tional and psychological support (Greenberg et al. 2020).
In the eventuality of a second wave of clinically significant SARS-CoV-2 pan-
demic, a return to a COVID-19-based healthcare service will have catastrophic con-
sequences for cancer patients and is also likely to exacerbate burnout amongst the 
oncology and wider healthcare workforce.2
3  Medical perspective
It is still too early to appreciate the direct and indirect impact of COVID-19 on 
oncology and on healthcare more broadly. However, there are some important points 
that need to be considered, particularly in the event of a new COVID-19 outbreak.
From a medical—and specifically oncological—perspective there have been calls 
to avoid compromising the delivery of care when the risk of COVID-19 infection 
(and any resulting complications) is outweighed by the benefits of treatment (Spicer 
et al. 2020).
It is also important to highlight that the oncology patient backlog, workforce 
burnout, and the other issues sketched above should not solely be attributed to the 
recent response to COVID-19. Oncology care (like most healthcare) was already 
under considerable pressure before the pandemic (Carrieri et  al. 2018). In many 
countries the increased demand for oncology care has not been followed by a rise 
in the oncology workforce and appropriate infrastructures (Sullivan et  al. 2011). 
Thus, COVID-19 has exacerbated pre-existing longstanding problems in oncol-
ogy care, which are in turn linked to a broader unpreparedness from a global health 
perspective.
2 https ://www.thegu ardia n.com/socie ty/2020/sep/05/more-than-1000-docto rs-want-to-quit-nhs-over-
handl ing-of-pande mic?CMP = Share _Andro idApp _Other (last accessed 07/09/2020).
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4  History of pandemics perspective
From a history of pandemics perspective, one of the most important issue raised by 
COVID-19 is the importance of preparedness. Historians of medicine coined terms 
such as ‘global amnesia’ to refer to a recurring pattern in human history to forget 
about pandemics as soon as they recede, and being unprepared once they re-emerge 
(Desai 2020). As Frank M. Snowden points out, one of the most significant and 
recent alarm bells was the report ‘A World at Risk’,3 published by the WHO in 2019 
(one year after the beginning of a new Ebola epidemic in the Democratic Republic 
of Congo), which concluded that the world and its individual countries were com-
prehensively unprepared for long-anticipated global health threats (Snowden 2019).
Despite these warnings, the world remained significantly unprepared, and such 
unpreparedness is ultimately linked to the global ‘tsunami’ of COVID-19 cases, and 
the reactive, hurried, and catastrophic curtailing of most oncology care to tackle the 
peak of the COVID-19 pandemic. Complex global threats like COVID-19 require 
complex system approaches, which must comprise appropriate prevention measures. 
We need more proactive strategies based on investments in sustainable public and 
global health, including the regular assessment of the likely global challenges and 
the development of means to meet them; investment in scientific research; enhanced 
healthcare infrastructure; and investments promoting close international collabora-
tion, innovative clinical training models, and health education (Snowden 2019).
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